



Humanigen

THE CYTOKINE STORM COMPANY

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of immunologic disorders including cancers and infectious diseases (COVID-19), by preventing and treating cytokine storm via its novel, anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) and Ephrin type-A receptor 3 (EphA3) monoclonal antibody neutralization molecules.

Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of: 1) cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions and 2) binding to EphA3 receptors found on many solid tumors.

PRODUCT PIPELINE

- **Lenzilumab demonstrated positive results in 520 patient Phase 3 clinical trial** for treatment of hospitalized patients with **COVID-19** pneumonia.
- The **ACTIV-5/BET-B** trial sponsored by **NIAID/NIH** has fully enrolled over **400 hospitalized COVID-19** patients with CRP levels <150 mg/L
- Pending confirmatory results from ACTIV-5/BET-B, **Humanigen plans to amend its EUA** to include these results
- **Humanigen anticipates** including ACTIV-5/BET-B-results in **filings with EMA and MHRA**
- Humanigen announced **positive data** in a Phase 1b study of lenzilumab in **diffuse large B-cell lymphoma (DLBCL)**, with plans to initiate a potential registrational Phase 2 study in 2022
- Potential registrational trials for **acute GvHD** to be initiated in 2022
- Enrollment in **CMML** continues

Two other pipeline candidates are currently in development for solid tumors, inadequately controlled asthma and other eosinophilic diseases.

- **Ifabotuzumab (iFab)**: anti-EphA3 monoclonal antibody currently being evaluated in solid tumors
- **HGEN005**: anti-EMR1 monoclonal antibody to be evaluated in severe eosinophilic diseases

PARTNERSHIPS

- Manufacturing Agreement with **Catalent** for lenzilumab
- Clinical Trial Agreement with **NIAID** in COVID-19
- Exclusive worldwide license agreement with the **University of Zurich** in GvHD
- Clinical Trial Agreement with **IMPACT Group** for aGvHD
- Pre-clinical Trial Agreement with **Olivia Newton John Cancer Center** for iFab ADC development
- Manufacturing agreement with **Chime Biologics** to produce lenzilumab bulk drug substance and drug product





TEAM

Humanigen, Inc. is led by a senior management team with extensive leadership experience in the biotechnology and pharmaceutical industries.

Chairman & CEO

Cameron Durrant, MD, MBA

Chief Scientific Officer

Dale Chappell, MD, MBA

Chief Operating Officer & Chief Financial Officer

Timothy E. Morris

Chief Medical Officer

Adrian Kilcoyne, MD, MBA

Head of Asia-Pacific Region

Bob Atwill, MBA

Chief Commercial Officer

Edward P. Jordan, MBA

Sr. Vice President, Investor Relations

Ken Trbovich

Sr. Vice President, Finance

Henry Madrid

CONTACT

Humanigen, Inc. U.S. Headquarters

830 Morris Turnpike, 4th Floor
Short Hills, NJ 07078-2625
650-243-3100
ir@humanigen.com

Humanigen Satellite Office

533 Airport Blvd, Suite 400
Burlingame, CA 94010-2013
ir@humanigen.com

Humanigen Europe Limited

2nd Floor, 1-2 Victoria Buildings, Haddington Road, Dublin 4
Dublin, Ireland, D04 XN32
HGEN-EULtd@humanigen.com

Humanigen Ltd.

5 Fleet Place
London, United Kingdom, EC4M 7RD
HGEN-UKLtd@humanigen.com

Humanigen Australia Proprietary Limited

("Humanigen Australia Pty Ltd"), please contact:
Bob Atwill, Head of Asia-Pacific Region
batwill@humanigen.com

Investor and Public Relations

ir@humanigen.com

Business Development

Bob Atwill
batwill@humanigen.com

Twitter

@humanigen

LinkedIn

linkedin.com/company/humanigen-inc

Facebook

@Humanigen

Website

www.humanigen.com

